/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma
S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma

S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma

OncLive® On Air · Oct 14, 2026

On-body subcutaneous isatuximab delivery streamlines clinic workflow and lays the groundwork for safe at-home multiple myeloma care.

Integrating On-Body Injectors Demands Multi-Nurse Verification and Separate EHR Templates

Adopting automated on-body injectors requires hospitals to adapt internal systems rather than simply stocking the medication. Institutions must establish physical workflows for two-nurse verification checks, manage distinct storage locations for device parts, and build specialized order templates within electronic health records.

S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma thumbnail

S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma

OncLive® On Air·a month ago

US At-Home Oncology Administration Lags Due to Unresolved Reimbursement and Staffing Frameworks

Although trial data proved at-home on-body delivery maintains identical efficacy and pharmacokinetics to clinic dosing, adoption remains limited internationally. Expansion in the United States is currently hindered by the lack of mobile healthcare provider administration models and undefined pharmacy reimbursement pathways.

S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma thumbnail

S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma

OncLive® On Air·a month ago

On-Body Delivery Shrinks Administration to Thirteen Minutes While Cutting Infusion Reactions

Transitioning multiple myeloma regimens to an on-body injector reduces clinic chair time from hours down to a median of thirteen minutes. In addition to improving workflow speed, the modality lowers infusion-related reaction rates and utilizes a retractable 30-gauge needle to mitigate needle-stick injuries.

S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma thumbnail

S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma

OncLive® On Air·a month ago